These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 20646482)
1. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma]. Huang ZJ; Luo Q; Yan JH; Wang SY Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482 [TBL] [Abstract][Full Text] [Related]
2. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice]. Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034 [TBL] [Abstract][Full Text] [Related]
4. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)₃-tTF. Huang ZJ; Zhao Y; Luo WY; You J; Li SW; Yi WC; Wang SY; Yan JH; Luo Q ScientificWorldJournal; 2013; 2013():637086. PubMed ID: 23861656 [TBL] [Abstract][Full Text] [Related]
5. [Gene expression and activities analysis of a new fusion protein (RGD) 3/tTF]. Yan JH; Yang GW; Wang JP; Wu N; Zhuang GH Sheng Wu Gong Cheng Xue Bao; 2007 May; 23(3):409-12. PubMed ID: 17577984 [TBL] [Abstract][Full Text] [Related]
6. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936 [TBL] [Abstract][Full Text] [Related]
8. [Expression and characterization of fusion protein tTF/SA as a universal effector for targeting blood coagulation]. Wang Z; Yan JH; Wang JP; Xie LY; Wu N Sheng Wu Gong Cheng Xue Bao; 2007 Mar; 23(2):218-22. PubMed ID: 17460891 [TBL] [Abstract][Full Text] [Related]
9. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR. Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827 [TBL] [Abstract][Full Text] [Related]
10. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180 [TBL] [Abstract][Full Text] [Related]
12. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging. Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effect and mechanism of action of a tumor-targeting recombinant human tumor necrosis factor-α fusion protein mediated by urokinase. Dai YC; Yang SM; Wang X; Zhou YJ; Hou G; Huang DN Mol Med Rep; 2015 Jun; 11(6):4333-40. PubMed ID: 25672264 [TBL] [Abstract][Full Text] [Related]
14. Fusion protein tTF-EG3287 induces occlusion of tumor vessels and impairs tumor growth in human colon caner. Qiu GQ; Xie X; Zhao B; Xu LZ; Chen YQ Neoplasma; 2019 Mar; 66(2):252-260. PubMed ID: 30569722 [TBL] [Abstract][Full Text] [Related]
15. A recombined fusion protein SP5.2/tTF induce thrombosis in tumor blood vessel. Lv S; Ye M; Wang X; Li Z; Chen X; Dou X; Dai Y; Zeng F; Luo L; Wang C; Li K; Luo X; Yan J; Li X Neoplasma; 2015; 62(4):531-40. PubMed ID: 25997964 [TBL] [Abstract][Full Text] [Related]
16. Antitumor Effect of Nanoparticle Ming H; Fang L; Gao J; Li C; Ji Y; Shen Y; Hu Y; Li N; Chang J; Li W; Tan J AJR Am J Roentgenol; 2017 May; 208(5):1116-1126. PubMed ID: 28301223 [TBL] [Abstract][Full Text] [Related]
17. The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET. Choi N; Kim SM; Hong KS; Cho G; Cho JH; Lee C; Ryu EK Biomaterials; 2011 Oct; 32(29):7151-8. PubMed ID: 21719102 [TBL] [Abstract][Full Text] [Related]
18. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. Huang FY; Li YN; Wang H; Huang YH; Lin YY; Tan GH J Zhejiang Univ Sci B; 2008 Aug; 9(8):602-9. PubMed ID: 18763309 [TBL] [Abstract][Full Text] [Related]
19. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma]. Song Y; Shen K; Yu JR Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307 [TBL] [Abstract][Full Text] [Related]
20. Expression and purification of rhIL-10-RGD from Escherichia coli as a potential wound healing agent. Yang F; Wan Y; Liu J; Yang X; Wang H; Tao K; Han J; Shi J; Hu D J Microbiol Methods; 2016 Aug; 127():62-67. PubMed ID: 27241829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]